First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan oleh Yasushi Goto, MD, PhD, Atsuhisa Tamura, MD, PhD, Hirotaka Matsumoto, MD, Kazutoshi Isobe, MD, PhD, Tomohiro Ozaki, MD, Melissa L. Santorelli, PhD, MPH, Kazuko Taniguchi, MS, Tetsu Kamitani, MD, PhD, Masato Irisawa, PhD, Kingo Kanda, MPharm, Machiko Abe, MS, Thomas Burke, PharmD, PhD, Hiroshi Nokihara, MD, PhD